Clinical immune characterization of hepatitis B virus infection and implications for immune intervention: Progress and challenges

Hepatology Research

Volumn 37, Issue SUPPL. 3, 2007, Pages

  Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

Adaptive immunity; Hepatitis B virus; Infection; Innate immunity; Liver

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; EMTRICITABINE; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CONFERENCE PAPER; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION RESISTANCE; INNATE IMMUNITY; KILLER CELL; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MEDICAL SPECIALIST; MOLECULAR MECHANICS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS CELL INTERACTION; VIRUS EXCRETION; VIRUS IMMUNITY;

EID: 35348838379     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00222.x     Document Type: Conference Paper

References (28)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
2. Ganem D, Prince AM. Hepatitis B virus infection: Natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-29.
4. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38: 4-13.
5. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 2006; 1: 23-61.
6. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605.
7. van der Molen RG, Sprengers D, Biesta PJ et al. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 2006; 44: 907-14.
8. Tang TJ, Kwekkeboom J, Mancham S et al. Intrahepatic CD8 T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol 2005; 43: 45-52.
9. Zhang Z, Wang FS. Plasmacytoid dendritic cells act as the most competent cell type in linking antiviral innate and adaptive immune responses. Cell Mol Immunol 2005; 2: 359-64.
10. Kakimi K, Guidotti LG, Koezuka Y et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-30.
11. Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117-24.
12. Nakamura H, Shimizu T, Ohshiro S et al. An adult patient with acute hepatitis type B which was protracted and complicated by polyarteritis nodosa: A case report. Hepatol Res 2002; 24: 439-44.
13. + regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322-8.
14. Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.
15. Xu D, Fu J, Jin L et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739-47.
16. Urbani S, Amadei B, Cariani E et al. The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection. J Immunol 2005; 175: 7519-29.
17. Grakoui A, Wherry EJ, Hanson HL et al. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol 2006; 45: 468-72.
18. Sobao Y, Tomiyama H, Sugi K et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002; 36: 105-15.
19. Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: Implications for immunotherapy. J Virol 2004; 78: 5707-19.
20. van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40: 738-76.
21. Untergasser A, Zedler U, Langenkamp A et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 2006; 43: 539-47.
22. Zhang Z, Chen D, Yao J et al. Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis B. Clin Immunol 2006; 122: 173-80. Epub 18 October 2006.
23. Gershwin ME, Vierling JM, Manns MP. Liver immunology. In: Mackay IR, ed. Hepatoimmunology: From Horizon to Harborside. Philadelphia, PA: Hanley & Belfus, 2003; 25-39.
24. Akbar SM, Furukawa S, Onji M et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004; 29: 136-41.
25. Chen M, Li YG, Zhang DZ et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B. A clinical study. World J Gastroenterol 2005; 11: 1806-8.
26. Hui CK, Lau GK. Advances in immunomodulating therapy of HBV infection. Int J Med Sci 2005; 2: 24-9.
27. Akbar SM, Horiike N, Onji M. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. World J Gastroenterol 2006; 12: 2876-83.
28. Shi M, Zhang B, Tang ZR et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1146-51.